Gene Therapy Market Size & Share Analysis Report - By Type (In vivo, Ex vivo), Vector Type (Viral, Non-Viral), Application (Oncology, Rare Diseases, Neurology, Ophthalmology, Hematology, Infectious Diseases, Cardiology), End User (Pharmaceutical and Biotechnology Companies, Academic Institutes and Research Centers) – Revenue Estimation and Forecast Through 2030

Chapter 1. Research Background

1.1 Research Objectives

1.2 Market Definition

1.3 Research Scope

1.3.1 Market Segmentation by Type

1.3.2 Market Segmentation by Vector Type

1.3.3 Market Segmentation by Application

1.3.4 Market Segmentation by End User

1.3.5 Market Segmentation by Geography

1.3.6 Analysis Period

1.3.7 Market Data Reporting Unit

1.4 Key Stakeholders

Chapter 2. Research Methodology

2.1 Secondary Research

2.2 Primary Research

2.2.1 Breakdown of Primary Research by Industry Participant

2.2.2 Breakdown of Primary Research by Company Type

2.3 Baseline Methodology

2.4 Market Size Estimation

2.5 KOLs’ Sources

2.6 Data Triangulation

2.7 Assumptions for the Study

Chapter 3. Executive Summary

Chapter 4. Introduction

4.1 Definition of Market Segments

4.1.1 By Type

4.1.1.1 In vivo

4.1.1.2 Ex vivo

4.1.2 By Vector Type

4.1.2.1 Viral

4.1.2.1.1 AAV

4.1.2.1.2 Lentivirus

4.1.2.1.3 Adenovirus

4.1.2.1.4 Retrovirus

4.1.2.1.5 Others

4.1.2.2 Non-viral

4.1.2.3 Others

4.1.3 By Application

4.1.3.1 Oncology

4.1.3.2 Rare diseases

4.1.3.3 Neurology

4.1.3.4 Ophthalmology

4.1.3.5 Hematology

4.1.3.6 Infectious diseases

4.1.3.7 Cardiology

4.1.3.8 Others

4.1.4 By End User

4.1.4.1 Pharmaceutical and biotechnology companies

4.1.4.2 Academic institutes and research centers

4.2 Market Dynamics

4.2.1 Trends

4.2.1.1 Increasing number of collaborations and partnerships

4.2.1.2 Evolution of the market with product launches

4.2.1.3 Outsourcing vector and gene therapy manufacturing

4.2.2 Drivers

4.2.2.1 Positive clinical results

4.2.2.2 Increasing therapy development activities

4.2.2.3 Surging burden of chronic diseases

4.2.2.4 Impact analysis of drivers on market forecast

4.2.3 Restraints

4.2.3.1 Cost-ineffectiveness of gene therapies

4.2.3.2 Long-term safety issues

4.2.3.3 Impact analysis of restraints on market forecast

4.2.4 Opportunities

4.2.4.1 Advances in the manufacturing facility

4.3 Porter’s Five Forces Analysis

Chapter 5. Global Market Size and Forecast

5.1 By Type

5.2 By Vector Type

5.2.1 Viral Vector Market, by Type

5.3 By Application

5.4 By End User

5.5 By Region

Chapter 6. North America Market Size and Forecast

6.1 By Type

6.2 By Vector Type

6.2.1 Viral Vector Market, by Type

6.3 By Application

6.4 By End User

6.5 By Country

6.5.1 U.S. Gene Therapy Market

6.5.1.1 By type

6.5.1.2 By vector type

6.5.1.2.1 Viral vector market, by type

6.5.1.3 By application

6.5.1.4 By end user

6.5.2 Canada Gene Therapy Market

6.5.2.1 By type

6.5.2.2 By vector type

6.5.2.2.1 Viral vector market, by type

6.5.2.3 By application

6.5.2.4 By end user

Chapter 7. Europe Market Size and Forecast

7.1 By Type

7.2 By Vector Type

7.2.1 Viral Vector Market, By Type

7.3 By Application

7.4 By End User

7.5 By Country

7.5.1 Germany Gene Therapy Market

7.5.1.1 By type

7.5.1.2 By vector type

7.5.1.2.1 Viral vector market, by type

7.5.1.3 By application

7.5.1.4 By end user

7.5.2 U.K. Gene Therapy Market

7.5.2.1 By type

7.5.2.2 By vector type

7.5.2.2.1 Viral vector market, by type

7.5.2.3 By application

7.5.2.4 By end user

7.5.3 France Gene Therapy Market

7.5.3.1 By type

7.5.3.2 By vector type

7.5.3.2.1 Viral vector market, by type

7.5.3.3 By application

7.5.3.4 By end user

7.5.4 Italy Gene Therapy Market

7.5.4.1 By type

7.5.4.2 By vector type

7.5.4.2.1 Viral vector market, by type

7.5.4.3 By application

7.5.4.4 By end user

7.5.5 Spain Gene Therapy Market

7.5.5.1 By type

7.5.5.2 By vector type

7.5.5.2.1 Viral vector market, by type

7.5.5.3 By application

7.5.5.4 By end user

Chapter 8. APAC Market Size and Forecast

8.1 By Type

8.2 By Vector Type

8.2.1 Viral Vector Market, By Type

8.3 By Application

8.4 By End User

8.5 By Country

8.5.1 China Gene Therapy Market

8.5.1.1 By type

8.5.1.2 By vector type

8.5.1.2.1 Viral vector market, by type

8.5.1.3 By application

8.5.1.4 By end user

8.5.2 Japan Gene Therapy Market

8.5.2.1 By type

8.5.2.2 By vector type

8.5.2.2.1 Viral vector market, by type

8.5.2.3 By application

8.5.2.4 By end user

8.5.3 India Gene Therapy Market

8.5.3.1 By type

8.5.3.2 By vector type

8.5.3.2.1 Viral vector market, by type

8.5.3.3 By application

8.5.3.4 By end user

8.5.4 South Korea Gene Therapy Market

8.5.4.1 By type

8.5.4.2 By vector type

8.5.4.2.1 Viral vector market, by type

8.5.4.3 By application

8.5.4.4 By end user

Chapter 9. LATAM Market Size and Forecast

9.1 By Type

9.2 By Vector Type

9.2.1 Viral Vector Market, by Type

9.3 By Application

9.4 By End User

9.5 By Country

Chapter 10. MEA Market Size and Forecast

10.1 By Type

10.2 By Vector Type

10.2.1 Viral Vector Market, By Type

10.3 By Application

10.4 By End User

10.5 By Country

Chapter 11. Competitive Landscape

11.1 Product Benchmarking of Key Players

11.2 Strategic Developments of Key Players

11.2.1 Product Approval/Launch

11.2.2 Acquisitions

11.2.3 Collaboration and Partnerships

11.2.4 Other Developments

Chapter 12. Company Profiles

12.1 Spark Therapeutics Inc.

12.1.1 Business Overview

12.1.2 Product and Service Offerings

12.2 bluebird bio Inc.

12.2.1 Business Overview

12.2.2 Product and Service Offerings

12.3 Orchard Therapeutics plc

12.3.1 Business Overview

12.3.2 Product and Service Offerings

12.3.3 Key Financial Summary

12.4 Amgen Inc.

12.4.1 Business Overview

12.4.2 Product and Service Offerings

12.4.2.1 Marketed products

12.4.2.2 Pipeline products

12.4.3 Key Financial Summary

12.5 REGENXBIO Inc.

12.5.1 Business Overview

12.5.2 Product and Service Offerings

12.5.3 Key Financial Summary

12.6 Thermo Fisher Scientific Inc.

12.6.1 Business Overview

12.6.2 Product and Service Offerings

12.6.3 Key Financial Summary

12.7 Applied Genetic Technologies Corporation

12.7.1 Business Overview

12.7.2 Product and Service Offerings

12.7.3 Key Financial Summary

12.8 Pfizer Inc.

12.8.1 Business Overview

12.8.2 Product and Service Offerings

12.8.3 Key Financial Summary

12.9 Adverum Biotechnologies Inc.

12.9.1 Business Overview

12.9.2 Product and Service Offerings

12.10 Novartis AG

12.10.1 Business Overview

12.10.2 Product and Service Offerings

12.10.3 Key Financial Summary

Chapter 13. Appendix

13.1 Abbreviations

13.2 Sources and References

13.3 Related Reports

 

LIST OF TABLES

 

TABLE 1 ANALYSIS PERIOD OF THE STUDY

TABLE 2 DRIVERS FOR THE MARKET: IMPACT ANALYSIS

TABLE 3 RESTRAINTS FOR THE MARKET: IMPACT ANALYSIS

TABLE 4 GLOBAL GENE THERAPY MARKET, BY TYPE, $M (2014–2019)

TABLE 5 GLOBAL GENE THERAPY MARKET, BY TYPE, $M (2020–2030)

TABLE 6 GLOBAL GENE THERAPY MARKET, BY VECTOR TYPE, $M (2014–2019)

TABLE 7 GLOBAL GENE THERAPY MARKET, BY VECTOR TYPE, $M (2020–2030)

TABLE 8 GLOBAL VIRAL VECTOR MARKET, BY TYPE, $M (2014–2019)

TABLE 9 GLOBAL VIRAL VECTOR MARKET, BY TYPE, $M (2020–2030)

TABLE 10 GLOBAL GENE THERAPY MARKET, BY APPLICATION, $M (2014–2019)

TABLE 11 GLOBAL GENE THERAPY MARKET, BY APPLICATION, $M (2020–2030)

TABLE 12 GLOBAL GENE THERAPY MARKET, BY END USER, $M (2014–2019)

TABLE 13 GLOBAL GENE THERAPY MARKET, BY END USER, $M (2020–2030)

TABLE 14 GLOBAL GENE THERAPY MARKET, BY REGION, $M (2014–2019)

TABLE 15 GLOBAL GENE THERAPY MARKET, BY REGION, $M (2020–2030)

TABLE 16 NORTH AMERICA GENE THERAPY MARKET, BY TYPE, $M (2014–2019)

TABLE 17 NORTH AMERICA GENE THERAPY MARKET, BY TYPE, $M (2020–2030)

TABLE 18 NORTH AMERICA GENE THERAPY MARKET, BY VECTOR TYPE, $M (2014–2019)

TABLE 19 NORTH AMERICA GENE THERAPY MARKET, BY VECTOR TYPE, $M (2020–2030)

TABLE 20 NORTH AMERICA VIRAL VECTOR MARKET, BY TYPE, $M (2014–2019)

TABLE 21 NORTH AMERICA VIRAL VECTOR MARKET, BY TYPE, $M (2020–2030)

TABLE 22 NORTH AMERICA GENE THERAPY MARKET, BY APPLICATION, $M (2014–2019)

TABLE 23 NORTH AMERICA GENE THERAPY MARKET, BY APPLICATION, $M (2020–2030)

TABLE 24 NORTH AMERICA GENE THERAPY MARKET, BY END USER, $M (2014–2019)

TABLE 25 NORTH AMERICA GENE THERAPY MARKET, BY END USER, $M (2020–2030)

TABLE 26 NORTH AMERICA GENE THERAPY MARKET, BY COUNTRY, $M (2014–2019)

TABLE 27 NORTH AMERICA GENE THERAPY MARKET, BY COUNTRY, $M (2020–2030)

TABLE 28 U.S. GENE THERAPY MARKET, BY TYPE, $M (2014–2019)

TABLE 29 U.S. GENE THERAPY MARKET, BY TYPE, $M (2020–2030)

TABLE 30 U.S. GENE THERAPY MARKET, BY VECTOR TYPE, $M (2014–2019)

TABLE 31 U.S. GENE THERAPY MARKET, BY VECTOR TYPE, $M (2020–2030)

TABLE 32 U.S. VIRAL VECTOR MARKET, BY TYPE, $M (2014–2019)

TABLE 33 U.S. VIRAL VECTOR MARKET, BY TYPE, $M (2020–2030)

TABLE 34 U.S. GENE THERAPY MARKET, BY APPLICATION, $M (2014–2019)

TABLE 35 U.S. GENE THERAPY MARKET, BY APPLICATION, $M (2020–2030)

TABLE 36 U.S. GENE THERAPY MARKET, BY END USER, $M (2014–2019)

TABLE 37 U.S. GENE THERAPY MARKET, BY END USER, $M (2020–2030)

TABLE 38 CANADA GENE THERAPY MARKET, BY TYPE, $M (2014–2019)

TABLE 39 CANADA GENE THERAPY MARKET, BY TYPE, $M (2020–2030)

TABLE 40 CANADA GENE THERAPY MARKET, BY VECTOR TYPE, $M (2014–2019)

TABLE 41 CANADA GENE THERAPY MARKET, BY VECTOR TYPE, $M (2020–2030)

TABLE 42 CANADA VIRAL VECTOR MARKET, BY TYPE, $M (2014–2019)

TABLE 43 CANADA VIRAL VECTOR MARKET, BY TYPE, $M (2020–2030)

TABLE 44 CANADA GENE THERAPY MARKET, BY APPLICATION, $M (2014–2019)

TABLE 45 CANADA GENE THERAPY MARKET, BY APPLICATION, $M (2020–2030)

TABLE 46 CANADA GENE THERAPY MARKET, BY END USER, $M (2014–2019)

TABLE 47 CANADA GENE THERAPY MARKET, BY END USER, $M (2020–2030)

TABLE 48 EUROPE GENE THERAPY MARKET, BY TYPE, $M (2014–2019)

TABLE 49 EUROPE GENE THERAPY MARKET, BY TYPE, $M (2020–2030)

TABLE 50 EUROPE GENE THERAPY MARKET, BY VECTOR TYPE, $M (2014–2019)

TABLE 51 EUROPE GENE THERAPY MARKET, BY VECTOR TYPE, $M (2020–2030)

TABLE 52 EUROPE VIRAL VECTOR MARKET, BY TYPE, $M (2014–2019)

TABLE 53 EUROPE VIRAL VECTOR MARKET, BY TYPE, $M (2020–2030)

TABLE 54 EUROPE GENE THERAPY MARKET, BY APPLICATION, $M (2014–2019)

TABLE 55 EUROPE GENE THERAPY MARKET, BY APPLICATION, $M (2020–2030)

TABLE 56 EUROPE GENE THERAPY MARKET, BY END USER, $M (2014–2019)

TABLE 57 EUROPE GENE THERAPY MARKET, BY END USER, $M (2020–2030)

TABLE 58 EUROPE GENE THERAPY MARKET, BY COUNTRY, $M (2014–2019)

TABLE 59 EUROPE GENE THERAPY MARKET, BY COUNTRY, $M (2020–2030)

TABLE 60 GERMANY GENE THERAPY MARKET, BY TYPE, $M (2014–2019)

TABLE 61 GERMANY GENE THERAPY MARKET, BY TYPE, $M (2020–2030)

TABLE 62 GERMANY GENE THERAPY MARKET, BY VECTOR TYPE, $M (2014–2019)

TABLE 63 GERMANY GENE THERAPY MARKET, BY VECTOR TYPE, $M (2020–2030)

TABLE 64 GERMANY VIRAL VECTOR MARKET, BY TYPE, $M (2014–2019)

TABLE 65 GERMANY VIRAL VECTOR MARKET, BY TYPE, $M (2020–2030)

TABLE 66 GERMANY GENE THERAPY MARKET, BY APPLICATION, $M (2014–2019)

TABLE 67 GERMANY GENE THERAPY MARKET, BY APPLICATION, $M (2020–2030)

TABLE 68 GERMANY GENE THERAPY MARKET, BY END USER, $M (2014–2019)

TABLE 69 GERMANY GENE THERAPY MARKET, BY END USER, $M (2020–2030)

TABLE 70 U.K. GENE THERAPY MARKET, BY TYPE, $M (2014–2019)

TABLE 71 U.K. GENE THERAPY MARKET, BY TYPE, $M (2020–2030)

TABLE 72 U.K. GENE THERAPY MARKET, BY VECTOR TYPE, $M (2014–2019)

TABLE 73 U.K. GENE THERAPY MARKET, BY VECTOR TYPE, $M (2020–2030)

TABLE 74 U.K. VIRAL VECTOR MARKET, BY TYPE, $M (2014–2019)

TABLE 75 U.K. VIRAL VECTOR MARKET, BY TYPE, $M (2020–2030)

TABLE 76 U.K. GENE THERAPY MARKET, BY APPLICATION, $M (2014–2019)

TABLE 77 U.K. GENE THERAPY MARKET, BY APPLICATION, $M (2020–2030)

TABLE 78 U.K. GENE THERAPY MARKET, BY END USER, $M (2014–2019)

TABLE 79 U.K. GENE THERAPY MARKET, BY END USER, $M (2020–2030)

TABLE 80 FRANCE GENE THERAPY MARKET, BY TYPE, $M (2014–2019)

TABLE 81 FRANCE GENE THERAPY MARKET, BY TYPE, $M (2020–2030)

TABLE 82 FRANCE GENE THERAPY MARKET, BY VECTOR TYPE, $M (2014–2019)

TABLE 83 FRANCE GENE THERAPY MARKET, BY VECTOR TYPE, $M (2020–2030)

TABLE 84 FRANCE VIRAL VECTOR MARKET, BY TYPE, $M (2014–2019)

TABLE 85 FRANCE VIRAL VECTOR MARKET, BY TYPE, $M (2020–2030)

TABLE 86 FRANCE GENE THERAPY MARKET, BY APPLICATION, $M (2014–2019)

TABLE 87 FRANCE GENE THERAPY MARKET, BY APPLICATION, $M (2020–2030)

TABLE 88 FRANCE GENE THERAPY MARKET, BY END USER, $M (2014–2019)

TABLE 89 FRANCE GENE THERAPY MARKET, BY END USER, $M (2020–2030)

TABLE 90 ITALY GENE THERAPY MARKET, BY TYPE, $M (2014–2019)

TABLE 91 ITALY GENE THERAPY MARKET, BY TYPE, $M (2020–2030)

TABLE 92 ITALY GENE THERAPY MARKET, BY VECTOR TYPE, $M (2014–2019)

TABLE 93 ITALY GENE THERAPY MARKET, BY VECTOR TYPE, $M (2020–2030)

TABLE 94 ITALY VIRAL VECTOR MARKET, BY TYPE, $M (2014–2019)

TABLE 95 ITALY VIRAL VECTOR MARKET, BY TYPE, $M (2020–2030)

TABLE 96 ITALY GENE THERAPY MARKET, BY APPLICATION, $M (2014–2019)

TABLE 97 ITALY GENE THERAPY MARKET, BY APPLICATION, $M (2020–2030)

TABLE 98 ITALY GENE THERAPY MARKET, BY END USER, $M (2014–2019)

TABLE 99 ITALY GENE THERAPY MARKET, BY END USER, $M (2020–2030)

TABLE 100 SPAIN GENE THERAPY MARKET, BY TYPE, $M (2014–2019)

TABLE 101 SPAIN GENE THERAPY MARKET, BY TYPE, $M (2020–2030)

TABLE 102 SPAIN GENE THERAPY MARKET, BY VECTOR TYPE, $M (2014–2019)

TABLE 103 SPAIN GENE THERAPY MARKET, BY VECTOR TYPE, $M (2020–2030)

TABLE 104 SPAIN VIRAL VECTOR MARKET, BY TYPE, $M (2014–2019)

TABLE 105 SPAIN VIRAL VECTOR MARKET, BY TYPE, $M (2020–2030)

TABLE 106 SPAIN GENE THERAPY MARKET, BY APPLICATION, $M (2014–2019)

TABLE 107 SPAIN GENE THERAPY MARKET, BY APPLICATION, $M (2020–2030)

TABLE 108 SPAIN GENE THERAPY MARKET, BY END USER, $M (2014–2019)

TABLE 109 SPAIN GENE THERAPY MARKET, BY END USER, $M (2020–2030)

TABLE 110 APAC GENE THERAPY MARKET, BY TYPE, $M (2014–2019)

TABLE 111 APAC GENE THERAPY MARKET, BY TYPE, $M (2020–2030)

TABLE 112 APAC GENE THERAPY MARKET, BY VECTOR TYPE, $M (2014–2019)

TABLE 113 APAC GENE THERAPY MARKET, BY VECTOR TYPE, $M (2020–2030)

TABLE 114 APAC VIRAL VECTOR MARKET, BY TYPE, $M (2014–2019)

TABLE 115 APAC VIRAL VECTOR MARKET, BY TYPE, $M (2020–2030)

TABLE 116 APAC GENE THERAPY MARKET, BY APPLICATION, $M (2014–2019)

TABLE 117 APAC GENE THERAPY MARKET, BY APPLICATION, $M (2020–2030)

TABLE 118 APAC GENE THERAPY MARKET, BY END USER, $M (2014–2019)

TABLE 119 APAC GENE THERAPY MARKET, BY END USER, $M (2020–2030)

TABLE 120 APAC GENE THERAPY MARKET, BY COUNTRY, $M (2014–2019)

TABLE 121 APAC GENE THERAPY MARKET, BY COUNTRY, $M (2020–2030)

TABLE 122 CHINA GENE THERAPY MARKET, BY TYPE, $M (2014–2019)

TABLE 123 CHINA GENE THERAPY MARKET, BY TYPE, $M (2020–2030)

TABLE 124 CHINA GENE THERAPY MARKET, BY VECTOR TYPE, $M (2014–2019)

TABLE 125 CHINA GENE THERAPY MARKET, BY VECTOR TYPE, $M (2020–2030)

TABLE 126 CHINA VIRAL VECTOR MARKET, BY TYPE, $M (2014–2019)

TABLE 127 CHINA VIRAL VECTOR MARKET, BY TYPE, $M (2020–2030)

TABLE 128 CHINA GENE THERAPY MARKET, BY APPLICATION, $M (2014–2019)

TABLE 129 CHINA GENE THERAPY MARKET, BY APPLICATION, $M (2020–2030)

TABLE 130 CHINA GENE THERAPY MARKET, BY END USER, $M (2014–2019)

TABLE 131 CHINA GENE THERAPY MARKET, BY END USER, $M (2020–2030)

TABLE 132 JAPAN GENE THERAPY MARKET, BY TYPE, $M (2014–2019)

TABLE 133 JAPAN GENE THERAPY MARKET, BY TYPE, $M (2020–2030)

TABLE 134 JAPAN GENE THERAPY MARKET, BY VECTOR TYPE, $M (2014–2019)

TABLE 135 JAPAN GENE THERAPY MARKET, BY VECTOR TYPE, $M (2020–2030)

TABLE 136 JAPAN VIRAL VECTOR MARKET, BY TYPE, $M (2014–2019)

TABLE 137 JAPAN VIRAL VECTOR MARKET, BY TYPE, $M (2020–2030)

TABLE 138 JAPAN GENE THERAPY MARKET, BY APPLICATION, $M (2014–2019)

TABLE 139 JAPAN GENE THERAPY MARKET, BY APPLICATION, $M (2020–2030)

TABLE 140 JAPAN GENE THERAPY MARKET, BY END USER, $M (2014–2019)

TABLE 141 JAPAN GENE THERAPY MARKET, BY END USER, $M (2020–2030)

TABLE 142 INDIA GENE THERAPY MARKET, BY TYPE, $M (2014–2019)

TABLE 143 INDIA GENE THERAPY MARKET, BY TYPE, $M (2020–2030)

TABLE 144 INDIA GENE THERAPY MARKET, BY VECTOR TYPE, $M (2014–2019)

TABLE 145 INDIA GENE THERAPY MARKET, BY VECTOR TYPE, $M (2020–2030)

TABLE 146 INDIA VIRAL VECTOR MARKET, BY TYPE, $M (2014–2019)

TABLE 147 INDIA VIRAL VECTOR MARKET, BY TYPE, $M (2020–2030)

TABLE 148 INDIA GENE THERAPY MARKET, BY APPLICATION, $M (2014–2019)

TABLE 149 INDIA GENE THERAPY MARKET, BY APPLICATION, $M (2020–2030)

TABLE 150 INDIA GENE THERAPY MARKET, BY END USER, $M (2014–2019)

TABLE 151 INDIA GENE THERAPY MARKET, BY END USER, $M (2020–2030)

TABLE 152 SOUTH KOREA GENE THERAPY MARKET, BY TYPE, $M (2014–2019)

TABLE 153 SOUTH KOREA GENE THERAPY MARKET, BY TYPE, $M (2020–2030)

TABLE 154 SOUTH KOREA GENE THERAPY MARKET, BY VECTOR TYPE, $M (2014–2019)

TABLE 155 SOUTH KOREA GENE THERAPY MARKET, BY VECTOR TYPE, $M (2020–2030)

TABLE 156 SOUTH KOREA VIRAL VECTOR MARKET, BY TYPE, $M (2014–2019)

TABLE 157 SOUTH KOREA VIRAL VECTOR MARKET, BY TYPE, $M (2020–2030)

TABLE 158 SOUTH KOREA GENE THERAPY MARKET, BY APPLICATION, $M (2014–2019)

TABLE 159 SOUTH KOREA GENE THERAPY MARKET, BY APPLICATION, $M (2020–2030)

TABLE 160 SOUTH KOREA GENE THERAPY MARKET, BY END USER, $M (2014–2019)

TABLE 161 SOUTH KOREA GENE THERAPY MARKET, BY END USER, $M (2020–2030)

TABLE 162 LATAM GENE THERAPY MARKET, BY TYPE, $M (2014–2019)

TABLE 163 LATAM GENE THERAPY MARKET, BY TYPE, $M (2020–2030)

TABLE 164 LATAM GENE THERAPY MARKET, BY VECTOR TYPE, $M (2014–2019)

TABLE 165 LATAM GENE THERAPY MARKET, BY VECTOR TYPE, $M (2020–2030)

TABLE 166 LATAM VIRAL VECTOR MARKET, BY TYPE, $M (2014–2019)

TABLE 167 LATAM VIRAL VECTOR MARKET, BY TYPE, $M (2020–2030)

TABLE 168 LATAM GENE THERAPY MARKET, BY APPLICATION, $M (2014–2019)

TABLE 169 LATAM GENE THERAPY MARKET, BY APPLICATION, $M (2020–2030)

TABLE 170 LATAM GENE THERAPY MARKET, BY END USER, $M (2014–2019)

TABLE 171 LATAM GENE THERAPY MARKET, BY END USER, $M (2020–2030)

TABLE 172 LATAM GENE THERAPY MARKET, BY COUNTRY, $M (2014–2019)

TABLE 173 LATAM GENE THERAPY MARKET, BY COUNTRY, $M (2020–2030)

TABLE 174 MEA GENE THERAPY MARKET, BY TYPE, $M (2014–2019)

TABLE 175 MEA GENE THERAPY MARKET, BY TYPE, $M (2020–2030)

TABLE 176 MEA GENE THERAPY MARKET, BY VECTOR TYPE, $M (2014–2019)

TABLE 177 MEA GENE THERAPY MARKET, BY VECTOR TYPE, $M (2020–2030)

TABLE 178 MEA VIRAL VECTOR MARKET, BY TYPE, $M (2014–2019)

TABLE 179 MEA VIRAL VECTOR MARKET, BY TYPE, $M (2020–2030)

TABLE 180 MEA GENE THERAPY MARKET, BY APPLICATION, $M (2014–2019)

TABLE 181 MEA GENE THERAPY MARKET, BY APPLICATION, $M (2020–2030)

TABLE 182 MEA GENE THERAPY MARKET, BY END USER, $M (2014–2019)

TABLE 183 MEA GENE THERAPY MARKET, BY END USER, $M (2020–2030)

TABLE 184 MEA GENE THERAPY MARKET, BY COUNTRY, $M (2014–2019)

TABLE 185 MEA GENE THERAPY MARKET, BY COUNTRY, $M (2020–2030)

TABLE 186 SPARK THERAPEUTICS INC. – AT A GLANCE

TABLE 187 BLUEBIRD BIO INC. – AT A GLANCE

TABLE 188 PIPELINE PRODUCTS

TABLE 189 ORCHARD THERAPEUTICS PLC – AT A GLANCE

TABLE 190 ORCHARD THERAPEUTICS PLC – KEY FINANCIAL SUMMARY

TABLE 191 AMGEN INC. – AT A GLANCE

TABLE 192 PIPELINE PRODUCTS

TABLE 193 AMGEN INC. – KEY FINANCIAL SUMMARY

TABLE 194 REGENXBIO INC. – AT A GLANCE

TABLE 195 REGENXBIO INC. – KEY FINANCIAL SUMMARY

TABLE 198 APPLIED GENETIC TECHNOLOGIES CORPORATION – AT A GLANCE

TABLE 199 APPLIED GENETIC TECHNOLOGIES CORPORATION – KEY FINANCIAL SUMMARY

TABLE 200 PFIZER INC. – AT A GLANCE

TABLE 201 PFIZER INC. – KEY FINANCIAL SUMMARY

TABLE 202 ADVERUM BIOTECHNOLOGIES INC. – AT A GLANCE

TABLE 203 NOVARTIS AG – AT A GLANCE

TABLE 204 NOVARTIS AG – KEY FINANCIAL SUMMARY

 

LIST OF FIGURES

 

FIG 1 RESEARCH SCOPE

FIG 2 RESEARCH METHODOLOGY

FIG 3 REGIONAL SPLIT OF PRIMARY AND SECONDARY RESEARCH

FIG 4 DATA TRIANGULATION APPROACH

FIG 5 GLOBAL GENE THERAPY MARKET SUMMARY

FIG 6 BARGAINING POWER OF BUYERS

FIG 7 BARGAINING POWER OF SUPPLIERS

FIG 8 INTENSITY OF RIVALRY

FIG 9 THREAT OF NEW ENTRANTS

FIG 10 THREAT OF SUBSTITUTES

FIG 11 GLOBAL GENE THERAPY MARKET SNAPSHOT, CAGR (2020-2030)

FIG 12 GLOBAL GENE THERAPY MARKET, BY TYPE, $M (2014–2030)

FIG 13 GLOBAL GENE THERAPY MARKET, BY VECTOR TYPE, $M (2014–2030)

FIG 14 GLOBAL GENE THERAPY MARKET, BY APPLICATION, $M (2014–2030)

FIG 15 GLOBAL GENE THERAPY MARKET, BY END USER, $M (2014–2030)

FIG 16 MAJOR MARKETS FOR GENE THERAPY

FIG 17 GLOBAL GENE THERAPY MARKET, BY REGION, $M (2014–2030)

FIG 18 NORTH AMERICA GENE THERAPY MARKET SNAPSHOT

FIG 19 NORTH AMERICA GENE THERAPY MARKET, BY TYPE, $M (2014–2030)

FIG 20 NORTH AMERICA GENE THERAPY MARKET, BY VECTOR TYPE, $M (2014–2030)

FIG 21 NORTH AMERICA GENE THERAPY MARKET, BY APPLICATION, $M (2014–2030)

FIG 22 NORTH AMERICA GENE THERAPY MARKET, BY END USER, $M (2014–2030)

FIG 23 NORTH AMERICA GENE THERAPY MARKET, BY COUNTRY, $M (2014–2030)

FIG 24 EUROPE GENE THERAPY MARKET SNAPSHOT

FIG 25 EUROPE GENE THERAPY MARKET, BY TYPE, $M (2014–2030)

FIG 26 EUROPE GENE THERAPY MARKET, BY VECTOR TYPE, $M (2014–2030)

FIG 27 EUROPE GENE THERAPY MARKET, BY APPLICATION, $M (2014–2030)

FIG 28 EUROPE GENE THERAPY MARKET, BY END USER, $M (2014–2030)

FIG 29 EUROPE GENE THERAPY MARKET, BY COUNTRY, $M (2014–2030)

FIG 30 APAC GENE THERAPY MARKET SNAPSHOT

FIG 31 APAC GENE THERAPY MARKET, BY TYPE, $M (2014–2030)

FIG 32 APAC GENE THERAPY MARKET, BY VECTOR TYPE, $M (2014–2030)

FIG 33 APAC GENE THERAPY MARKET, BY APPLICATION, $M (2014–2030)

FIG 34 APAC GENE THERAPY MARKET, BY END USER, $M (2014–2030)

FIG 35 APAC GENE THERAPY MARKET, BY COUNTRY, $M (2014–2030)

FIG 36 LATAM GENE THERAPY MARKET SNAPSHOT

FIG 37 LATAM GENE THERAPY MARKET, BY TYPE, $M (2014–2030)

FIG 38 LATAM GENE THERAPY MARKET, BY VECTOR TYPE, $M (2014–2030)

FIG 39 LATAM GENE THERAPY MARKET, BY APPLICATION, $M (2014–2030)

FIG 40 LATAM GENE THERAPY MARKET, BY END USER, $M (2014–2030)

FIG 41 LATAM GENE THERAPY MARKET, BY COUNTRY, $M (2014–2030)

FIG 42 MEA GENE THERAPY MARKET SNAPSHOT

FIG 43 MEA GENE THERAPY MARKET, BY TYPE, $M (2014–2030)

FIG 44 MEA GENE THERAPY MARKET, BY VECTOR TYPE, $M (2014–2030)

FIG 45 MEA GENE THERAPY MARKET, BY APPLICATION, $M (2014–2030)

FIG 46 MEA GENE THERAPY MARKET, BY END USER, $M (2014–2030)

FIG 47 MEA GENE THERAPY MARKET, BY COUNTRY, $M (2014–2030)

FIG 48 PRODUCT BENCHMARKING OF KEY PLAYERS

FIG 49 AMGEN INC. – REVENUE SPLIT BY MARKETED PRODUCTS AND GEOGRAPHY (2019)

FIG 50 THERMO FISHER SCIENTIFIC INC. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)

FIG 51 PFIZER INC. – REVENUE SPLIT BY OPERATING SEGMENT AND GEOGRAPHY (2019)

FIG 52 NOVARTIS AG – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2019)